Osimertinib has been used as a first-line treatment in NSCLC patients with EGFR Mutations due to significant therapeutic effects on both common EGFR mutations (Del19 and L858R) and T790M resistance mutations (Popat, 2018). Here, EGFR is linked to non-small cell lung carcinoma.